Chloropvrimidine intermediates

Abstract

The present invention relates to certain novel pyrimidine intermediates and their salts, processes for their preparation and processes for their conversion to 9-substituted-2-aminopurines which are useful in medical therapy.

1 . A process for the preparation of a compound of formula (VII)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is hydrogen; hydroxyl; a C 3-7  carbocyclic group, optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; an acyclic group, wherein such acyclic groups may be optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; or a C 4-7  heterocyclic group, wherein said C 4-7  heterocyclic group has a one or more heteroatoms selected from the group consisting of a N, O and S atom and wherein such C 4-7  heterocyclic group may be optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; provided that such groups are not attached by a glycosidic bond, comprising reacting a compound of formula (VI)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is as defined above, with a trialkylorthoformate in the presence of an aqueous acid.  
     
     
         2 . A process for the preparation of a compound of formula (VII)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is a C 3-7  carbocyclic group, optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; an acyclic group, wherein such acyclic group may be optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; or a C 4-7  heterocyclic group, wherein said C 4-7  heterocyclic group has a one or more heteroatoms selected from the group consisting of a N, O and S atom and wherein such C 4-7  heterocyclic group may be optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; provided that such groups are not attached by a glycosidic bond, comprising reacting a compound of formula (VI)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is as defined above, with a trialkylorthoformate in the presence of an aqueous acid.  
     
     
         3 . A process for the preparation of the compound of formula (VII)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is selected from:  
       
         
           
           
               
               
           
         
       
       b. H;  
       
         
           
           
               
               
           
         
       
       d. ( CH   3   C(O) CH 2 ) 2 CHCH 2 CH 2 -;  
       
         
           
           
               
               
           
         
       
       comprising reacting a compound of formula (VI)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is as defined above with a trialkylorthoformate in the presence of an aqueous acid.  
     
     
         4 . A process for the preparation of a compound of formula (VII)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is comprising reacting a compound of formula (VI)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is as defined above with a trialkyorthoformate in the presence of an aqueous acid.  
     
     
         5 . A process according to  claim 1 , wherein R 3  is a C 3-7  carbocyclic group.  
     
     
         6 . A process for the preparation of a compound of formula (VII)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is an acyclic group, wherein such acyclic group may be optionally substituted with substituents selected from the group consisting of C 1-4  alkyl, C 1-4  alkoxy, hydroxyl or protected hydroxyl, azido, phosphonyl, and halogen; provided that such groups are not attached by a glycosidic bond, comprising reacting a compound of formula (VI)  
       
         
           
           
               
               
           
         
       
       wherein R 3  is as defined above, with a trialkylorthoformate in the presence of an aqueous acid.